CoChat

Exploring the wider benefits of semaglutide treatment in obesity: insight from the STEP program.

Open access
O’Neil, Patrick M., Rubino, Domenica M. · 2022 · Postgraduate Medicine

The DOI matches its Crossref record; 54 of the 54 references it cites were found in a registry or an index.

Abstract

Obesity negatively impacts patients’ health-related quality of life (QOL) and is associated with a range of complications such as type 2 diabetes (T2D), cardiovascular disease, and sleep apnea, alongside decreased physical function, mobility, and control of eating. The Semaglutide Treatment Effect in People with obesity (STEP) trials compared once-weekly subcutaneous semaglutide 2.4 mg with placebo in adults with overweight or obesity, with or without T2D. This article reviews the effects of semaglutide 2.4 mg on QOL, control of eating, and body composition. Weight-related QOL was assessed using the Impact of Weight on Quality of Life-Lite Clinical Trials Version (IWQOL-Lite-CT), and health-related QOL was assessed with the 36-item Short Form Health Survey version 2 (SF-36v2®). Control of eating was evaluated using the Control of Eating questionnaire in a subgroup of participants in one trial. Body composition was evaluated via dual-energy x-ray absorptiometry in another trial, in a subgroup of participants with a body mass index of ≤40 kg/m2. All IWQOL-Lite-CT scores (Physical Function, Physical, Psychosocial, and Total Score) improved with semaglutide 2.4 mg significantly more than with placebo. Across the trials, changes in SF-36v2 scores were generally in favor of semaglutide versus placebo. There were significant improvements in all Control of Eating questionnaire domains (craving control, craving for savory, craving for sweet, and positive mood) up to week 52 with semaglutide treatment versus placebo, with improvements in craving control and craving for savory remaining significantly different at week 104. Body composition findings showed that reductions in total fat mass were greater with semaglutide versus placebo. These findings highlight the wider benefits that patients can experience with once-weekly subcutaneous semaglutide 2.4 mg, in addition to weight loss, including improvements in patients’ wellbeing and ability to perform daily activities. Taken together, these are important considerations for primary care when incorporating pharmacotherapy for weight management.

Overview

Integrity signals

Registry

Crossref · 10.1080/00325481.2022.2150006

Cites

54 of 54 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 54 references

Research works printed but not linked: 6

  1. Blomain ES, 2013, ISRN Obes, 2013, 210524
  2. Garvey TW, 2021, Abstract presented at the 39th Annual Meeting of the Obesity Society at ObesityWeek® [Oral 096]
  3. Wharton S, 2021, Abstract presented at the 39th Annual Meeting of the Obesity Society at ObesityWeek® [Oral 095]
  4. Maruish ME, 2011, QualityMetric Inc.
  5. Rubino DM, 2021, Obes Facts, 14, 1, 10.1159/000509134 · DOI
  6. Rubino D, Presentation at the 81st Scientific Sessions of the American Diabetes Association

Cited by

See all 27

Metadata

Authors
O’Neil, P. M., & Rubino, D. M.
Affiliations
  • Weight Management Center, Department of Psychiatry and Behavioral Sciences, Medical University of South Carolina, Charleston, SC, USA
  • Washington Center for Weight Management and Research (US)
Corresponding author
Rubino, Domenica M.
Venue
Postgraduate Medicine
Published
2022-04-14
Volume
134
Issue
sup1
Pages
28-36
ISSN
  • 0032-5481 (ISSN-L)
  • 1941-9260
OpenAlex
W4317871309
Cited by
19
References
54
Citations by year
2026: 2 · 2025: 9 · 2024: 7 · 2023: 1
FWCI
0.61
Type
journal article
Language
en
Open access
Locations
  • Postgraduate Medicine (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
Funders
Novo Nordisk Inc
Topics
  • Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
Keywords
semaglutide, obesity, weight management, health-related quality of life, weight-related quality of life, food intake regulation, body composition, fat mass reduction, type 2 diabetes, STEP program, primary care
MeSH terms
Semaglutide, Adult, Diabetes Mellitus, Type 2, Glucagon-Like Peptides, Humans, Hypoglycemic Agents, Obesity, Quality of Life

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Exploring the wider benefits of semaglutide treatment in obesity: insight from the STEP program. https://app.cochat.ai/papers/10.1080/00325481.2022.2150006
The paper
O’Neil, P. M., & Rubino, D. M. (2022). Exploring the wider benefits of semaglutide treatment in obesity: insight from the STEP program. Postgraduate Medicine. https://doi.org/10.1080/00325481.2022.2150006

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.